The financials came out and it has failed to impress the markets as the numbers out of Greece were pretty good but dropped in Canada for Pennsaid and their burn rate is high because of the additional testing the FDA has forced them to do. The stock will probably trickle down in the mean time as the stock basically waits for the tests to come to completion towards the end of this year.